The relationship between type 2 diabetes, obesity and NAION is complex, says Meenal Agarwal, MD, optometrist and host of the podcast Uncover Your Eyes
These side effects typically resolve on their own without treatment
Severe allergy to semaglutide or any ingredient in Wegovy
L-Carnitine Supports fat oxidation and energy production, enhancing the effects of Semaglutide
50.5% achieved at least 15% weight loss
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status